Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, about the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought BioAge stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3][8]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in relation to the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted, suggesting a robust trial design and execution [5]. - The company discontinued the STRIDES Phase 2 study after subjects exhibited elevated liver enzyme levels, indicating potential organ damage, which was not disclosed in prior trials [6]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting its own history of successful settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].
BIOA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA